Briefs: Alembic Pharma and IOL Chemicals and Pharmaceuticals
USFDA inspection at Alembic Pharma's Bioequivalence facility
USFDA inspection at Alembic Pharma's Bioequivalence facility
Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase
The company will provide the necessary response on these observations to USFDA within stipulated 15 days
The observations issued are neither repeated observations nor related to data integrity
USFDA inspection at Emcure Pharmaceuticals API facility
Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Subscribe To Our Newsletter & Stay Updated